Related Experiment Video
Updated: Feb 25, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Assessment of Specificity of an Adenovirus Targeted to HER3/4
Sheena H MacLeod1, Kyle G Potts2, Shyambabu Chaurasiya2,3
1Department of Oncology, University of Alberta, Edmonton, AB, Canada. shm@ualberta.ca.
Abstract:
Gene therapy with viral vectors, such as adenovirus (Ad), targeted to the human epidermal growth factor receptors 3 and 4 (HER3/4) are potentially useful for cancer therapy. Testing the expression of a reporter gene from these viruses in target cells is essential to determine functionality of the targeted virus. A competition assay with a relevant ligand (heregulin, HRG) can provide convincing evidence that blocking binding to the HER3/4 receptor results in decreased reporter gene expression. Labeling individual viruses with a fluorescent molecule allows examination of the targeted virus in specific steps in the infection. Virus internalization into cell lines can be determined using antibody-labeled receptors, and the virus colocalization with receptors can also be visualized. Characterization of a targeted virus in this fashion is important to demonstrate that the targeting of the virus functions in an expected manner, and provides support for larger-scale testing of the virus. Information acquired in these experiments may also be useful to inform and improve on the design of future targeted viruses.
Insights
Targeted gene therapy using adenovirus (Ad) vectors for HER3/4 receptors shows promise for cancer treatment. Assays confirm virus targeting and functionality, crucial for further development.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Gene therapy utilizing viral vectors, like adenovirus (Ad), is a promising avenue for cancer treatment.
- Targeting specific receptors, such as human epidermal growth factor receptors 3 and 4 (HER3/4), enhances therapeutic precision.
- Assessing the functionality of targeted viral vectors is critical for their clinical application.
Purpose of the Study:
- To validate the targeting efficacy and functionality of adenovirus vectors engineered to bind HER3/4 receptors.
- To establish methods for characterizing targeted viral vector-cell interactions in vitro.
- To provide a foundation for the development of improved targeted oncolytic viruses.
Main Methods:
- Utilized adenovirus (Ad) vectors engineered for HER3/4 receptor targeting.
- Employed a reporter gene expression system to assess viral transduction efficiency.
- Conducted competition assays using heregulin (HRG) to confirm receptor-specific binding.
- Visualized virus-receptor interactions using fluorescently labeled viruses and antibodies.
Main Results:
- Demonstrated that reporter gene expression from targeted Ad vectors is dependent on HER3/4 receptor binding.
- Confirmed that heregulin competition significantly reduces reporter gene expression, validating specific targeting.
- Visualized virus internalization and colocalization with HER3/4 receptors in target cells.
- Established a robust methodology for characterizing targeted viral vector performance.
Conclusions:
- The developed adenovirus vectors effectively target HER3/4 receptors on cancer cells.
- The experimental methods confirm the functionality and specificity of the targeted viral vectors.
- These findings support the advancement of HER3/4-targeted gene therapy for cancer treatment.
- The study provides valuable insights for the design of next-generation targeted viral therapies.
